Meeting
2012 ASCO Annual Meeting
Vorinostat, temozolomide, and bevacizumab for patients with recurrent glioblastoma: A phase I/II trial.
Authors
Katherine B. Peters
Duke University Medical Center, Durham, NC
Katherine B. Peters , James J. Vredenburgh , Annick Desjardins , Henry S. Friedman , James Emmett Herndon II, April D. Coan , Frances McSherry , Eric S Lipp , Alise Brickhouse , Woody C Massey , David A. Reardon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Clinical Trial Registration Number
NCT00939991
Citation
J Clin Oncol 30, 2012 (suppl; abstr 2027)
DOI
10.1200/jco.2012.30.15_suppl.2027
Abstract #
2027
Poster Bd #
15
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR-amplified recurrent glioblastoma.
First Author: Yoshitaka Narita
Poster
2016 ASCO Annual Meeting
Phase I/II study of VAL-083 in patients with recurrent glioblastoma.
First Author: Kent C. Shih
Poster
2016 ASCO Annual Meeting
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
First Author: Martin J. Van Den Bent
Poster
2015 ASCO Annual Meeting
Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
First Author: Ashley Ghiaseddin